<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DCE508CA-70B7-43EC-99A2-3197E0AA3077"><gtr:id>DCE508CA-70B7-43EC-99A2-3197E0AA3077</gtr:id><gtr:name>Ono Pharmaceutical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4BBE223-561B-4B1A-A4BF-315A828FAEAE"><gtr:id>C4BBE223-561B-4B1A-A4BF-315A828FAEAE</gtr:id><gtr:name>MRC-Technology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DCE508CA-70B7-43EC-99A2-3197E0AA3077"><gtr:id>DCE508CA-70B7-43EC-99A2-3197E0AA3077</gtr:id><gtr:name>Ono Pharmaceutical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4BBE223-561B-4B1A-A4BF-315A828FAEAE"><gtr:id>C4BBE223-561B-4B1A-A4BF-315A828FAEAE</gtr:id><gtr:name>MRC-Technology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECF22327-6842-49CB-A398-31B6AAD9B89A"><gtr:id>ECF22327-6842-49CB-A398-31B6AAD9B89A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Tobin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/145BDD79-0BC7-4AEA-88AA-FBCB01E51457"><gtr:id>145BDD79-0BC7-4AEA-88AA-FBCB01E51457</gtr:id><gtr:firstName>Ruth</gtr:firstName><gtr:otherNames>Caroline</gtr:otherNames><gtr:surname>Barber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/775E1533-901D-47C8-953C-C9172D318B65"><gtr:id>775E1533-901D-47C8-953C-C9172D318B65</gtr:id><gtr:firstName>Phil</gtr:firstName><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15045"><gtr:id>8C3B80FC-F0AE-4CD9-B33D-A20D0CBCB67E</gtr:id><gtr:title>Extending Translational Biomedical Research At The University Of Leicester</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15045</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GSK Oncology</gtr:department><gtr:description>BCL6 i in lymphoma</gtr:description><gtr:id>E4349528-2015-41F7-81E5-C865695A7214</gtr:id><gtr:impact>It is hoped that this programme of work will ultimatly result in a 'to clinic' drug but we are currently in the early lead identification phase of the drug discovery pipeline</gtr:impact><gtr:outcomeId>58cbb67b38c744.16237297-1</gtr:outcomeId><gtr:partnerContribution>GSK are providing on-going structural biology data to support a med chem programme and are also developing novel assays to demonstrate target engagement</gtr:partnerContribution><gtr:piContribution>We have provided structural biology information and early cellular data to provide target validation. We are now supporting a GSK lead Med Chem programme by providing complex celluar and pre-clinical models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ono Pharmaceutical</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>BTK Resistance</gtr:description><gtr:id>124E93B5-17FC-43DB-B0B5-65E90314696D</gtr:id><gtr:impact>Outputs include - development of resistant lines, with full genetic analysis, the development of PDX models of lymphoid disease.</gtr:impact><gtr:outcomeId>58cbb6e6371748.76174455-1</gtr:outcomeId><gtr:partnerContribution>A member of Ono staff has been working with in Leicester to develop and assay models of BTK resistance</gtr:partnerContribution><gtr:piContribution>Working with individuals from Ono we have been using our access to a unique catalog of lymphoid cell lines to model resistance to BTK inhibition. Support has also been supplied for the development of PDX models of DLBCL</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nedd8</gtr:description><gtr:id>D516CD9B-8399-479D-9988-27E933CD6361</gtr:id><gtr:impact>This partnership is still in it's early stages but we hope to and plan to write (in collaboration with Domianex) for translational grant applications (CR-UK, MRC-DPFS etc) to gain additional funding to progress this project</gtr:impact><gtr:outcomeId>58cbb5d329a802.97007100-1</gtr:outcomeId><gtr:partnerContribution>Domainex for a STAR award (awarded in July 2015 ~ value &amp;pound;10,000). This award has lead to an in silico screen of the Domainex LeadBuilder library of 1.2 million collated 'lead-like' molecules - the outputs of which are now being validated</gtr:partnerContribution><gtr:piContribution>The 2014/15 CiC award was used to optimise our novel in-house assays to detect the catalytic activity of the COP9 complex which along with the 2.6 A?. These data enabled us to win a competitive award from Domainex (the STAR Award for in silico screening) and we are now in the process of validating hits from the Domianex in silico screen</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC-Technology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Explant</gtr:description><gtr:id>C4120FBD-4D4B-42C1-90DA-453A77DE6C0A</gtr:id><gtr:impact>A number of publications have used this methodology (prior to MRC funding from this source) and a number of additional publications are anticipated (in the next 6 months) alongside further collaborations with other tech transfer companies</gtr:impact><gtr:outcomeId>58cbb55a512be3.85530452-2</gtr:outcomeId><gtr:partnerContribution>MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to it's current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds.</gtr:partnerContribution><gtr:piContribution>The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research Technology (CRT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Explant</gtr:description><gtr:id>C1878D5B-5208-4F82-AE49-9AAFD7CB036A</gtr:id><gtr:impact>A number of publications have used this methodology (prior to MRC funding from this source) and a number of additional publications are anticipated (in the next 6 months) alongside further collaborations with other tech transfer companies</gtr:impact><gtr:outcomeId>58cbb55a512be3.85530452-1</gtr:outcomeId><gtr:partnerContribution>MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to it's current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds.</gtr:partnerContribution><gtr:piContribution>The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>Explant</gtr:description><gtr:id>E3223711-F9AA-4396-8C75-03CF161B29AD</gtr:id><gtr:impact>A number of publications have used this methodology (prior to MRC funding from this source) and a number of additional publications are anticipated (in the next 6 months) alongside further collaborations with other tech transfer companies</gtr:impact><gtr:outcomeId>58cbb55a512be3.85530452-3</gtr:outcomeId><gtr:partnerContribution>MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to it's current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds.</gtr:partnerContribution><gtr:piContribution>The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Girlguiding</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A40B9682-B5C5-46F7-981E-FF734FDB61C9</gtr:id><gtr:impact>Multiple events within Girlguiding Leicestershire - 1) age appropriate hands on activities performed with girls from 4-17 to make science fun and engaging - with the purpose of promoting Science Technology Engineering and Maths (STEM) activities to young women (small groups - individual meetings and also to division/county events including camps and activity days) 2) training sessions for leaders in Girlguiding to enable/encourage them to undertake STEM activities within thier units 3) to promote Women In Science and Engineering (WISE) 4) provide positive female role models</gtr:impact><gtr:outcomeId>58cbc0119ab7a0.39517990</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CR UK Outreach</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3569111F-607D-4B60-9D5A-FB2D17FBCF49</gtr:id><gtr:impact>Engagement with activities organised as part of the Cancer Research UK Leicester Centre. Typically bi-annual events are put on to engage with the general public with hands on activities, talks, films and discussions (inc Q&amp;amp;A sessions).</gtr:impact><gtr:outcomeId>58cbc058e03212.21868792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MCB Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>16013BF7-C6E8-4820-BDB4-39247B845A78</gtr:id><gtr:impact>Open day to school children from across the region for widening participation purposes. Hands on activities explaining 'precision medicine' were undertaken</gtr:impact><gtr:outcomeId>58cbc12a23e800.76250201</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2A5E3C65-D119-4D90-87C9-E4F2C7006A88</gtr:id><gtr:impact>Talks given on malaria research - typically to a year group (60-80 students) - discussions, Q&amp;amp;A sessions to follow and careers advice given. Typically 3-4 such events are undertaken annually.</gtr:impact><gtr:outcomeId>58cbbfb7729f22.42819867</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Group Talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CC97DDD8-7A96-4228-AB60-D30191E08D20</gtr:id><gtr:impact>Talks about advances in drug discovery research at the University (special emphasis on lung/thoracic and haematological diseases). Typically 'after dinner style' talks with Q&amp;amp;A sessions.</gtr:impact><gtr:outcomeId>58cbc0f09fccf5.75905237</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits to UofL</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9541DE6D-FA5E-4DDA-99C3-E69833DB9089</gtr:id><gtr:impact>Participation in Dynamic DNA and Richard III open days - which open up the University to children and members of the general public. Typically a mixture of hands on activities (covering science subjects and other activities of note for the University e.g. archeology). The positive effects are increased engagement with the local (and wider community) and in widening participation (making a University education more approachable for all).</gtr:impact><gtr:outcomeId>58cbc0a85dbd77.42229611</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PDX Project</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Hope Against Cancer (Rutland and Leicestershire)</gtr:fundingOrg><gtr:id>0E99852B-C1DE-43A6-92B8-88E91E5F54C5</gtr:id><gtr:outcomeId>58cbb832a9a9b1.86593526</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Molecular Diagnostics</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Hope Against Cancer (Rutland and Leicestershire)</gtr:fundingOrg><gtr:id>EE7B8928-0815-4B1A-B657-369F3F4672B3</gtr:id><gtr:outcomeId>58cbb7e5623251.47401901</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC grant funding</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>C9923900-685F-44BD-B7CB-CC343BFCFE8F</gtr:id><gtr:outcomeId>58cbb7a267b7a3.10684213</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Wellcome Trust Seed Awards in Science</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>1079914/Z/15/Z</gtr:fundingRef><gtr:id>D8948888-45E3-4DA1-AB7B-D62E9AEA27A1</gtr:id><gtr:outcomeId>58cbb75c667087.36741161</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Using an ex vivo tissue explant to model patient responses to standard of care and novel drug therapies</gtr:description><gtr:id>505AA91E-B900-473B-BB66-A316E247BEE7</gtr:id><gtr:impact>We have been sharing information and developing the methodology in collaboration with CRT (2015-present) and MRCT (contract in negotiation). These data are to validate the predictive ability of the current model (with a focus on NSCLC) to predict patient responses. We have also tested some novel agents - these data have been used (in part) to make decisions on which molecules to take forward into additional pre-clinical (including animal) models.</gtr:impact><gtr:outcomeId>58cbc16c7f03f3.01776717</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Explant Project</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>415475D8-1F41-4765-B97E-7524C03F5F2A</gtr:id><gtr:title>Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb21aa48b34d485576459cda583d6cbe"><gtr:id>bb21aa48b34d485576459cda583d6cbe</gtr:id><gtr:otherNames>Karekla E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58cbb1b2774512.73948323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C70E56B7-13A6-479A-ACAC-E2F8DCA23B2B</gtr:id><gtr:title>Aortic dissection.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a07e13a8b4e12b4dd1676b3cb1719407"><gtr:id>a07e13a8b4e12b4dd1676b3cb1719407</gtr:id><gtr:otherNames>Nienaber CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn><gtr:outcomeId>5a9c64b711c264.59671626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC214DD9-9C5F-4CA2-A781-F2A4308BD1F8</gtr:id><gtr:title>PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c19642f90fbc335a85092953a5ddd64c"><gtr:id>c19642f90fbc335a85092953a5ddd64c</gtr:id><gtr:otherNames>Rieck B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5a93f4f6507d26.67963107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CF309B2-65A9-4C3E-98CC-9273CC5FFC93</gtr:id><gtr:title>Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58549a498b0a6059f6c52433c2769e31"><gtr:id>58549a498b0a6059f6c52433c2769e31</gtr:id><gtr:otherNames>Beck D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58cbb143e432e2.69658436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D75038A-723B-4B3F-B92F-0D4878BC3767</gtr:id><gtr:title>Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases.</gtr:title><gtr:parentPublicationTitle>European heart journal. Acute cardiovascular care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03d4fdb4a700578ff3369686ce0847aa"><gtr:id>03d4fdb4a700578ff3369686ce0847aa</gtr:id><gtr:otherNames>Suzuki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2048-8726</gtr:issn><gtr:outcomeId>5a9c653cdb2958.87552052</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15045</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>